# An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

> **NCT06021054** · PHASE3 · COMPLETED · sponsor: **Viridian Therapeutics, Inc.** · enrollment: 188 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** Veligrotug (VRDN-001)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06021054
- **Lead sponsor:** Viridian Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-14
- **Primary completion:** 2024-11-04
- **Final completion:** 2025-07-25
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06021054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06021054, "An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06021054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*